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The terms ‘mucositis’ and ‘stomatitis’ are often used interchangeably. Mucositis, however, pertains to
pharyngeal-esophago-gastrointestinal inflammation that manifests as red, burn-like sores or ulcerations
throughout the mouth. Stomatitis is an inflammation of the oral tissues proper, which can present with or
without sores, and is made worse by poor dental hygiene. Mucositis is observed in a variety of immun-
osuppressed patients, but is most often consequential to cancer therapy. It appears as early as the third
day of intervention, and is usually established by Day 7 of treatment. Mucositis increases mortality
and morbidity and contributes to rising health care costs. The precise immune components involved
in the etiology of mucositis are unclear, but evidence-based research (EBR) data has shown that applica-
tions of granulocyte–macrophage-colony stimulating factor prevent the onset or the exacerbation of oro-
pharyngeal mucositis. The molecular implications of this observation are discussed from the perspective
of future developments of complementary and alternative treatments for this condition. It must be
emphasized that this article is meant to be neither a review on mucositis and the various treatments
for it, nor a discussion paper on its underlying molecular immunology. It is a statement of the implica-
tions of EBR for CAM-based interventions for mucositis. It explores and discusses the specific domain
of molecular immunology in the context of mucositis and its direct implications for EBR research in
CAM-based treatments for mucositis.
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Mucositis
The terms ‘mucositis’ and ‘stomatitis’ are often used
interchangeably. Mucositis, however, pertains to pharyngeal-
esophago-gastrointestinal inflammation that manifests as red,
burn-like sore or ulcerations throughout the mouth. Stomatitis
is an inflammation of the oral tissues proper, which can present
with or without sores, and is made worse by poor dental
hygiene.
Oropharyngeal mucositis is a common and treatment-
limiting side effects of immune suppression, such as those
directed by the cytotoxic action of cancer therapy. It is an acute
oral mucosal inflammatory reaction secondary to cell death of
the basal cell lining of the oral mucosa. Oral microorganisms
play an important role in aggravating the pathology of the
impaired epithelium. Smoking, and alcohol use and abuse, and
psycho-emotional stress are also relevant factors. Clinically
observed atrophy (tissue damage) and telangiectasis (blood
vessel, spider-like red spots) of the mucosa increase the risk
for pain and/or necrosis. Mucositis leads to systemic immune
suppression, and to an increased risk of local and generalized
infection, opportunistic infections and mortality due to sepsis.
Mucositis is common among oncology patients. Whereas
early estimates proposed that mucositis occurred in over 40%
of patients who receive cancer chemotherapy or irradiation
(1), more recent data indicate that oral and gastrointestinal
mucositis can affect up to 100% of patients undergoing
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transplantation, 80% of patients with malignancies of the
head and neck receiving radiotherapy, and over 50% of
patients receiving chemotherapy (2).
The severity of mucositis depends from the type of cancer,
the schedule and nature of the chemotherapy intervention,
the area irradiated and the amount of radiation given. In the
case of radiation therapy, if it is delivered at a rate equivalent
to the ability of the oral mucosa to regenerate, then only mild
mucositis occurs. Chemotherapy treatment given by continu-
ous infusion or frequent, repetitive, intermittent schedules are
more likely to cause mucositis than the same drugs given by
a single short infusion. Severe oral mucositis can lead to the
need to interrupt or discontinue the cancer therapy protocol,
thus hindering cure of the primary disease. Impairments of
local oral immunity, and consequential infection are common
manifestations of mucositis, and appropriate diagnosis and
antimicrobial treatment interventions must be considered for
both fungal and bacterial organisms. Viral infections are rarely
a complication of mucositis (2–4).
A five-step model of mucositis has been proposed (4) to help
explain the clinical features of the condition. The five phases
of oropharyngeal mucositis are:
(i) initiation;
(ii) upregulation and message generation;
(iii) signaling and amplification;
(iv) ulceration; and
(v) healing.
These phases may be observed to occur simultaneously and
recur cyclically in any given patient. The model offers a
rational approach for understanding the fundamental pathobio-
logy and for targeting various components of the pathologic
process for research into therapeutic interventions (4).
The molecular and cellular pathways that lead to mucositis
are unclear. Research suggests that the condition represents
the culmination of a dynamic sequence of three distinct events
in the oropharyngeal mucosa:
(i) keratinocyte toxicity and death;
(ii) impaired mucosal immune surveillance; and
(iii) significant alterations in oral flora (5).
These events can lead to ulcerative lesions in the oropharynx
that can be so painful as to restrict oral intake of food and
liquids. These lesions can also act as sites of secondary
infection and portals of entry for the endogenous flora in the
stoma (1).
Palliative and Therapeutic Treatment
Oropharyngeal mucositis manifests as inflammation, which
can be severe and leading to lesions and ulcerations of the
mucosa, and which can significantly impair the daily function-
ing and quality of life of the patients. Current care of patients
with mucositis is essentially palliative and includes appropri-
ate oral hygiene, non-irritating diet and oral care products,
topical mouth rinses, topical anesthetics and opioid analgesics.
Topical anesthetics (Viscous Xylocaine ) have been reported
to be of some value, unless the pain requires systemic
analgesic drugs. Despite our understanding that the loss of
rapidly dividing epithelial progenitor cells triggers the onset
of the disorder, the severity and duration of the condition are
determined largely by changes in local immunity, which lead
to changes in oral flora. The complexity of the pathobiological
processes that lead to mucositis preclude the development and
testing of effective treatment, despite the fact that the model of
the disease outlined above permits an experimental approach
for elucidating its biological mechanisms, including the
molecular and cellular pathways leading to inflammation,
disease and injury of the cells and tissues in the mucosa (6–8).
In oncology patients, management of mucositis may require,
in some cases, a 1 week interruption of cancer therapy. Pro-
gress in the prevention and management of mucositis will
improve quality of life, reduce cost of care, and facilitate com-
pletion of more intensive cancer chemotherapy and radio-
therapy protocols. Improved management of mucositis will
also allow implementation of cancer treatment protocols that
are currently excessively mucotoxic but may produce higher
cure rates. In these patients, the severity of mucositis depends
upon the aggressive nature of the cancer therapy, the patient’s
state of immune suppression, the patient’s white blood cell
count, and the patient’s general oral health and hygiene.
Whether or not smoking and drinking behaviors may con-
tribute to mucositis is still controversial (9–11). When local
impairment of immune surveillance and consequential infec-
tion are not present, mucositis can heal by itself (12).
A short course of systemic prednisone (40–80 mg daily for
not more than 1 week) is often recommended, and has been
helpful in reducing inflammation and discomfort. Bioactive/
growth factors, hormones or interleukins have also been found
to be effective for modifying epithelial metabolism and redu-
cing the susceptibility of the tract to mucositis. Protective
mucosal coatings such as sucralfate, alone or in combination
with antibiotics and analgesics, help reduce mucositis and its
associated pain and discomfort. Anti-inflammatory drugs,
such as triclosan and indometacin reduce the duration and
severity of mucositis in some cases and topical applications
of vitamin A and E also have been used in attempts to reduce
mucositis. The use of low-energy laser therapy can reduce
the incidence of mucositis and enhance epithelial healing (7).
Recent developments in evidence-based medical care (13)
permit a stringent evaluation of the literature. It must be
emphasized that evidence-based research (EBR) in medicine
rests on systematic reviews. This is quite distinct and different
from medicine based on the evidence, which pertains to the
traditional approach of modern Western medicine that relies
on a few (or single) published communications. EBR in medi-
cine refers to the practice of medicine grounded on the con-
sensus statement obtained from the systematic research on all
available published reports.
Results of one systematic review indicate that ice chips
(odds ratio, OR ¼ 0.42; 95% confidence interval (CI) ¼
0.19–0.93) and benzydamine have the strongest scientific
evidence of support for prophylaxis of mucositis (14). In
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prophylaxis of mucositis caused by conventional fractionated
head and neck radiotherapy, and cryotherapy for short half-
life stomatoxic chemotherapy, such as bolus fluorouracil (3).
A Cochrane-sponsored systematic review has also shown that
several interventions have some benefit at preventing
or reducing the severity of mucositis associated with cancer
treatment. The data indicate that these benefits are specific
for certain cancer types and treatment. The findings estab-
lished, moreover, that the number needed to treat (NNT) to
prevent one patient experiencing mucositis over a baseline
incidence of 60% for amifostine is NNT ¼ 33 (CI
95 ¼
20–100), for antibiotic paste or pastille NNT ¼ 13 (CI
95 ¼
8–50) and for ice chips NNT ¼ 5 (CI
95 ¼ 2–31) (11).
Whereas the precise immune components involved in
the etiology of mucositis are unclear, EBR has established
that applications of granulocyte–macrophage-colony stimu-
lating factor (GM-CSF) prevent the onset or the exacerbation
of oropharyngeal mucositis (risk ratio, RR ¼ 0.51,
CI
95 ¼ 0.29–0.91; NNT ¼ 3, CI
95 ¼ 2–20) (11). Clinical
trials suggest that GM-CSF has clinical benefits beyond
enhancing neutrophil recovery, including shortening the dura-
tion of mucositis and diarrhea (15), stimulating dendritic cells,
preventing infection, acting as an adjuvant vaccine agent and
facilitating antitumor activity (16).
The colony-stimulating factors (CSFs) are a family of
cytokines central to the development and maturation of cells
of the immune system, the modulation of their functional
responses, as well as the maintenance of immune homeostasis
and overall immunity. This group of glycoproteins consists of
the macrophage-CSF (M-CSF), granulocyte-CSF (G-CSF),
GM-CSF and multi-CSF [interleukin(IL)-3]. GM-CSF func-
tions at early stages of lineage commitment regulating the
expansion and maturation of hematopoietic progenitor cells
(17). GM-CSF is a proinflammatory cytokine that stimulates
proliferation and differentiation of neutrophilic, eosinophilic
and monocytic lineages of cellular immunity. In immunosup-
pressed patients, and in murine models of therapeutic immune
suppression, GM-CSF administration is effective in boosting
the innate immune response, while continuing to suppress the
adaptive immune response to prevent graft rejection (18).
Molecular Immunology
Molecular cartography, the science of recognizing and identi-
fying the multifaceted and intricate array of interacting genes
and gene products that characterize the function and special-
ization of each individual cell in the context of cell–cell
interaction, tissue and organ function, and system’s biology
in general, is among the most promising and cutting-edge
trends in the health sciences today. DNA sequencing techno-
logy of the 1970s and the 1980s gave way to genomics, the
characterization of proteomics, and the validation of the inter-
actome, the map of all possible interactions among genes and
gene products in the organism in response to stimuli from
within (e.g. hormonal response to challenges, viral infection),
and from challenges that come from outside the organism
(e.g. alcohol use and abuse). The analysis of gene expression
in tissues, cells and biologic systems by microarray allows
discovery-based research to characterize either new genes
with unknown function or genes not previously known to be
involved in a biologic process (19). Integrating interactome
maps with systematic genetic perturbations will be useful for
developing a systems biology approach to this and other
signaling modules (20).
The relevance of molecular cartography in immunology
pertains to every domain of physiology, including immunity.
Molecular cartography provides the fundamental knowledge
and understanding of the genomic, the proteomic and inter-
actomic processes that regulate the emergence, stability and
function of immune cell populations, and the mechanisms by
which new populations arise following antigenic triggers and
immune activation. Molecular cartography of immunity also
produces new fundamental knowledge with respect to the pro-
cesses that determine the functional response of immune cells,
such as, for instance, the ability of immune T cells to produce
cytokines or to migrate across an endothelial barrier toward an
antigen (5).
The value of molecular cartography in immunology lies not
only in the characterization of the fundamental biologic mech-
anisms that control and regulate immune processes and events
in the healthy individual, but as well, and perhaps more
importantly, in revealing the modes and modalities by which
the organism adapts to physiological insults and stressful
challenges, injury (e.g. the injurious sequelae of smoking or
alcohol) and disease (e.g. cancer).
Molecular cartography also plays a critical role in the
elucidation of pathological processes, including mucositis,
and in the development of novel or improved modes of treat-
ment interventions. Careful study of the genome, proteome
and interactome provides essential new knowledge about the
process of disease. This is one of the most attractive features
of molecular cartography for pharmaceutical companies,
which labor to develop new vaccine protocols and new
therapeutic drugs. Molecular cartography, or ‘meta-genomics’
as it is often labeled in the context of the drug development
industry, is promising, but it is also fraught with problems
and caveats due in part to our limited knowledge and under-
standing, at present, of the gargantuan nature of these systems,
due to the emerging realization that genes and their protein
products have the potential of interacting in a multitude of
ways, and because drugs targeted to specific molecular path-
ways have the potential of producing troubling side effects.
Case in point is the role of GM-CSF in the SOCS pathway,
which may underlie the pathobiological process of mucositis.
The activation of the family of suppressors of cytokine signal-
ing (SOCS) has direct effects on transmembrane and tran-
scytosolic signaling pathways that are central to immune cell
activation, and that involve the janus kinase/signal transducer
and activator of transcription (JAK/STAT) and the Ras path-
ways (5). The activation of these pathways is essential for
dendritic cell differentiation and maturation. STAT6 signaling
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dendritic populations and declines as these cells mature. This
sequence of molecular events is associated with a marked
induction of SOCS1, SOCS2, SOCS3, as well as cytokine-
induced Src homology 2-containing protein expression.
STAT1 signaling is not altered during the maturation process
of dendritic cells, remains unaffected by SOCS, but is optim-
ally induced by IL-4 and GM-CSF. IL-4, in turns, specifically
activates SOCS-1, whereas GM-CSF activates SOCS-3 during
the maturation of dendritic cells (21).
AkT [phosphoinositide 3-kinase, also known as protein
kinase B (PKB)] and the tumor suppressor, PTEN (phos-
phatase and tensin homolog deleted on chromosome 10, which
removes phosphates primarily from lipids), also play an
important role in modulating signaling events, including Ras,
and functional cellular immune responses, including activation
and migration. The other important pathway related to SOCS
is the P3 member of the first forkhead-box (FOX) transcription
factor (FoxP3). FoxP3 functions as a transcriptional repressor,
targeting composite NF-AT/AP-1 sites in cytokine gene pro-
moters. The region responsible for NF-AT inhibition has
been mapped to the amino terminus of FoxP3. Molecular
experiments show that introduction of FoxP3 into conven-
tional mouse T cells converts these cells to the regulatory T




  cells can
be converted to the CD25
þ Treg phenotype following in vitro
stimulation, with associated acquisition of Treg-like function,
and induction of FoxP3 expression (22–24). Proteins that
interact with nucleophosmin-anaplastic lymphoma kinase
(NPM-ALK) tyrosine kinase also play important roles in
mediating downstream cellular signals. These, identified
by microarray include, PI3-K, JAK2, JAK3, STAT3, Grb2,
IRS, and PLCgamma1, Rho-GTPase activating protein
(RAB35), kinases (MEK kinase 1 and 4, PKC, MLCK, cyclin
G-associated kinase, EphA1, JNK kinase, MAP kinase 1),
phosphatases (meprin, PTPK, protein phosphatase 2 subunit),
and heat shock proteins (Hsp60 precursor), as well as
SOCS (25).
CD28 ligation increases the proliferative response of both
CD4
þ and CD8
þ T cell subsets via these molecular pathways.
The response of the CD4
þ subset is more marked in
terms, particularly, of 5-fold increase in GM-CSF, compared





 ) is the most
CD28-responsive lymphocyte population to CD28-mediated
costimulation (26). CD25
þCD4
þ Tregs are required for the
maintenance of peripheral tolerance to certain self antigens.
The suppressive function of Tregs is critically dependent
on immature myeliod dendritic cells and is reversed by the
maturation of this cell population induced by GM-CSF (27).
The GM-CSF/IL-3/IL-5 receptors are a family of hetero-
dimeric transmembrane proteins expressed by dendritic cells
and other myeloid lineage cells, which also transmit activation
signals through these complex pathways. Each receptor has a
unique ligand-binding a chain, but they share a common
bc chain. Binding of GM-CSF activates JAK2, which rapidly
induces tyrosine phosphorylation of the bc chain, but not the
a chain. Molecular mutation experiments, however, have
established that bc chain tyrosine residues are not necessary
for activation of the JAK/STAT pathway, or for proliferation,
viability, or adhesion signaling, although they significantly
increase the magnitude of these responses (28). That
GM-CSF and its receptor are expressed in the brain, and
appear to play an important role in modulating various peri-
pheral and central nervous system functions (29) suggests
an important neuroimmune role of GM-CSF in the etiology
of mucositis, which could be exploited for novel modes of
treatment intervention.
In this context, it is possible and even probable that research
will uncover a neuronal receptor/ligand interaction (e.g.
GM-CSF) with Treg cells that under stress may inhibit the
inhibitory action of the FoxP3 interaction with NF-AT/AP-1
sites in cytokine promoters. Indeed, lymphocytes express sev-
eral neuron-like (e.g. b-adrenergic) and hormonal receptors
(e.g. glucocorticoids, ACTH, opioid), whose transmembrane
signaling could alter FoxP3, and SOCS and the associated
signaling network.
In closing, and recalling the recent findings of the vagal
efferents on immune suppression (30), psychosocial stress,
which is an important etiological factor for mucositis, could
soon be shown to alter the expression of the acetylcholin-
esterase gene. This gene product is now known to present
in at least three alternative proteins that are implicated in
a wide variety of regulatory mind–body responses. Stress-
induced alternative gene splicing such as this could become a
major mind–body pathway of psychosocial genomics, particu-
larly in terms of the immunopathology of mucositis, in the
coming decade (31).
We have established in previous studies a direct link
between the parasympathetic glossopharyngeal innervation
(CN IX) and immune surveillance of the oropharyngeal
mucosa (32). We predict that future genomic research will
uncover the fundamental signaling pathways that are involved
in the pathological processes of mucositis: keratinocyte death,
which lead to suppression of immune surveillance, and that
result in bacterial and fungal invasion of the stoma. Together
these advances will lead to improved traditional, complement-
ary and alternative treatment for patients with mucositis.
Implications for Interventions in
Complementary and Alternative
Medicine (CAM)
The purpose of this paper was not meant to explore and discuss
in an exhaustive fashion the several excellent papers written in
the domain of mucositis, which would be akin to generating a
traditional narrative review.Rather, we sought to cross the new
frontier of the evidence-based discourse, and to focus on what
is known and available in the systematically reviewed body of
evidence: in EBR in mucositis. We examined the implications
of EBR for the development of CAM-based interventions, with
the focal point of interest being not every and all pathological
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immunity. The one treatment for mucositis that rests upon
molecular immune pathways of this disease, and that has been
examined by means of systematic EBR is GM-CSF-based
intervention.
Immediate relevance and applications of the findings we
discuss in this paper will pertain to the clinical treatment
of mucositis. This is critical since in 2004 alone, close to
1.5 million Americans were diagnosed with cancer and
received some combination therapies for this disease, includ-
ing surgery, radiation, chemotherapy, immunotherapy and/or
cell transplantation. A range of side effects accompanies these
different types of cancer therapy, from the mild and transient
alopecia, nausea and neutropenia, to the chronic signs of
fatigue and lymphedema, to the late and potentially life threat-
ening cardiomyopathy, and to severe oral manifestations.
Mucositis, the principal oral complication from cancer therap-
ies is common and can substantially impair the comfort and
function of patients during and after the treatment protocol,
and the patient’s willingness to adhere to or complete the
prescribed therapy (7).
The clinical significance of mucositis is heightened by the
fact that not only individuals undergoing cancer therapy are
at risk but also immunosuppressed patients in general, includ-
ing subjects who are seropositive for the immunodeficiency
virus-1 (HIV) with or without full-blown acquired immune
deficiency syndrome (AIDS) (33,34). The elderly as well are
at risk, and older subjects have increased sensitivity to oral
toxicity, in particular, mucositis (35).
EBR in complementary and alternative interventions for
mucositis has established that prophylactic administration of
scavenger or anti-inflammatory agents can block or reverse
the etiology of this condition. Mouthwashes and gargling
agents may be beneficial complementary interventions for
patients with oral mucositis, in that these treatments may
shorten the duration and severity of symptoms. The regular
use of mouthwashes, mouth coatings, antibiotics and anal-
gesics has been shown to be essential, before and during loss
and ablation of the epithelial layer. Glutamine supplements
seem to be beneficial in the repair and recovery phase (7).
Few controlled clinical trials of psychological interventions
for pain relief exist inspite of frequent support fortheir import-
ance as adjuncts to medical treatment, particularly in the
context of mucositis-associated distress. In a study of pain
associated with oral mucositis, cancer patients receiving bone
marrow transplants were administered therapist support,
relaxation and imagery training, cognitive-behavioral coping
skills with relaxation and imagery, or placebo control. Patients
who received either relaxation and imagery alone, the package
of cognitive-behavioral coping skills with added relaxation
and imagery reported significantly less pain, compared with
patients in the other groups. Cognitive-behavioral skills were
not more beneficial than relaxation and imagery alone
(P ¼ 0.103), suggesting relaxation and imagery training,
whether by itself or in conjunction with cognitive skills
reduces cancer treatment-related mucositis. Training patients
in cognitive-behavioral skills in addition to relaxation with
imagery failed to further improve outcomes (36). A systematic
review conducted following the stringent protocol and recom-
mendations of EBR in medicine further confirmed the value of
relaxation and imagery as a complementary medicine inter-
vention in oral mucositis in terminal cancer patients under
radiation or chemotherapy treatment (37).
Alternative interventions to Western pharmaceutical treat-
ment involve traditional Asian herbal medicine. For instance,
the Japanese herb Syousaikotou was tested as a gargling agent
for patients receiving chemotherapy, as a proactive measure
against the onset of mucositis. Compared with the Placebo
group that used a mouthwash of providone-iodine and ampho-
tericin B, the Syousaikotou gargle group showed a signific-
antly decreased incidence of stomatitis, and significantly
reduced oral mucosal irritation, inflammation and pain. Side
effects of Syousaikotou treatment were limited to <10% of
the patients treated, who complained of halitosis and of oil
and grass smells (38). In related study, oral administration of
the putative antioxidant oren-gedoku-to (Japanese, Coptidis
rhizoma; Huanglin-Jie-Du-Tang in Chinese pharmacopoeia)
reduced significantly incidence of mucositis and of stomatitis
(27.9%), compared with 71.6% in those who received a gargle
consisting of the placebo group treated with allopurinol,
sodium gualenate and povidone-iodine (71.6%). Herbal treat-
ment also significantly decreased anticancer intervention-
induced diarrhea (9.3%), compared with the placebo group
(31.7%) (39). Evidence-based systematic reviews of the
research evidence on the effectiveness and efficacy of herbal
medicine in the treatment of mucositis are lacking to date.
Taken together and despite current advances in knowledge
and fundamental molecular understanding of the etiology and
the immunopathology of mucositis, it is clear from current
EBR that the limited number of available clinical trials pre-
cludes the recommendation of one over another treatment
intervention for mucositis. Future advances will depend upon
well-designed and well-conducted studies with sufficient
numbers of participants to perform subgroup analyses by
type of disease (2,11).
In conclusion, this paper discussed three main domains of
mucositis. It began by defining it, then discussed what is
known about treatments, and examined the fundamental
molecular immunology of mucositis. This discussion, within
the cadre of evidence-based medicine and CAM, led to an
evaluation of the relevance to evidence-based CAM, the focal
point of the paper, its raison d’e ˆtre in light of immediate
potential relevance and applications to the clinical treatment
of mucositis.
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